ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

INSPIRE Enrollment Stopped; Thromboembolism Risk Cited

February 25, 2011

Glaxo, Mass General Begin Phase III Trial Of Tykerb

December 29, 2006

In Brief: Albert and Mary Lasker Foundation announce 2014 award winners

September 12, 2014

FDA News: FDA Lifts Clinical Hold On CTI’s Tosedostat

January 31, 2014

Modeling Will Be Used For Other Populations

November 26, 2010

Amgen Web Site For Patients Goes Dark After Story In The Cancer Letter.

November 16, 2007